Beyond Tacrolimus: Toward Personalized Immunosuppression in Heart Transplantation
Journal of Cardiac Failure · 2026
DOI: 10.1016/j.cardfail.2026.06.017 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cardiac Failure, 2026. Verfasst von Marc D Samsky und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago IL, USA. Hauptthemen laut MEDLINE: Heart Transplantation, Immunosuppressive Agents, Precision Medicine, Tacrolimus. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Heart Association-American Stroke Association, NIAID NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Heart transplantation remains the definitive treatment for end-stage heart failure, and contemporary immunosuppressive regimens, typically a calcineurin inhibitor, antiproliferative agent, and corticosteroids applied with minimal preemptive individualization, despite profound heterogeneity in recipient immune biology, pharmacokinetics, comorbidity burden, and alloimmune risk. This review examines the case for personalized immunosuppression in heart transplantation across 4 domains. First, we survey the current landscape of immunosuppression, identify key gaps, and discuss emerging strategies. Second, we review the evolving toolbox of posttransplant immune monitoring and molecular biomarkers, including donor-specific antibodies, gene-expression profiling, donor-derived cell-free DNA, and technologies in development, appraising their clinical evidence, performance characteristics, and limitations. Third, we propose a framework for integrating existing tools into composite risk assessment and for developing new approaches to individualized patient management. Finally, we outline future directions for the field, including preimplantation graft gene editing, AI-assisted donor-recipient matching, and continuous risk assessment. Realizing the potential of personalized immunosuppression in heart transplantation will require not only a broader suite of validated biomarkers and integrative risk scores but also novel pragmatic trial designs and surrogate endpoints to support the development of next-generation therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago IL, USA.
- Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
- Ajmera Transplant Centre, University Health Network, Toronto, Canada.
- Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago IL, USA.
- Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago IL, USA; Inova Schar Heart and Vascular, Falls Church, VA, USA. Electronic address: Palak.shah@northwestern.edu.
Förderung
- American Heart Association-American Stroke Association
- NIAID NIH HHS
- NHLBI NIH HHS
- American Heart Association Inc
- National Institute of Allergy and Infectious Diseases
- National Heart Lung and Blood Institute
- National Institutes of Health
Zitieren
APA
Samsky, M. D., Farr, M. A., Parikh, A. G., Moayedi, Y., Tambur, A. R., & Shah, P. (2026). Beyond Tacrolimus: Toward Personalized Immunosuppression in Heart Transplantation. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2026.06.017
Vancouver
Samsky MD, Farr MA, Parikh AG, Moayedi Y, Tambur AR, Shah P. Beyond Tacrolimus: Toward Personalized Immunosuppression in Heart Transplantation. Journal of Cardiac Failure. 2026. doi:10.1016/j.cardfail.2026.06.017
BibTeX
@article{Samsky2026,
author = {Samsky, Marc D and Farr, Maryjane A and Parikh, Aditya G and Moayedi, Yasbanoo and Tambur, Anat R and Shah, Palak},
title = {Beyond Tacrolimus: Toward Personalized Immunosuppression in Heart Transplantation},
journal = {Journal of Cardiac Failure},
year = {2026},
doi = {10.1016/j.cardfail.2026.06.017}
}
EUVIMED